Avoro Capital Issues Open Letter to Fellow Acceleron Pharma Shareholders
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/7/2026
- Nasdaq set to fall at open as DeepSeek's AI chip push rattles markets
- Oil gains after vessels attacked near Strait of Hormuz
- Citi says SpaceX stock has path to $900+ valuation. Here’s how
- Tesla stock target lifted at RBC on potential SpaceX merger
- Short squeezes more likely than widespread selling: Citi
- Rivian Automotive (RIVN) files for 75M share offering
- Rivian offers Q2 2026 revenue outlook, cash position grows
- Nokia OYJ (NOKIA:FH) (NOK) PT Raised to EUR14 at Kepler Cheuvreux
- Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
- Coursera plans layoffs after Udemy merger, estimates $8M-$11M in costs
Merck (MRK) PT Raised to $90 at Morgan Stanley on Gardasil Strength
October 29, 2021 8:46 AM EDTMorgan Stanley analyst Matthew Harrison raised the price target on Merck (NYSE: MRK) to $90.00 (from $88.00) while maintaining a Equalweight rating after 3Q total revenue beat expectations driven primarily by Gardasil sales due to strong global demand and increased supply. Management expects robust... More
